Ashley Jeudy-Hypolite's Company Details
Montreal, QC, CA • 1000 - 4999 Employees
Major Drugs
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 56th among Canada's top 100 Research & Development (R&D) investors with over $43 million invested in 2018, Pharmascience Inc. is the 4th largest manufacturer of over-the-counter generic drugs in the country.
Excellence opérationelle en fabrication et distribution de médicaments génériques - Industrie pharmaceutique //
Operational excellence in manufacturing and distributing of generic drugs - Pharmaceutical Industry
Pharmascience inc. fabrique et commercialise des médicaments génériques vendus avec ordonnance
en vente libre et distribués par le pharmacien
ainsi que des médicaments injectables fabriqués au Canada et approuvés par la Food and Drug Administration (FDA)
Pharmascience Inc. is a leading manufacturer and marketer of prescription generic
over-the-counter
and behind-the-counter products as well as FDA approved Canadian-made injectables.
L’entreprise commercialise près de 300 familles de produits sous 20 formes de dosages distincts
ce qui représente plus de 2 000 produits.
The company commercializes nearly 300 product families in 20 different dosage forms for over 2
000 products.
Depuis plus de 20 ans
l’entreprise collabore avec Partenaires Canadiens pour la Santé Internationale (HPIC) dans le but d’aider l’organisme à accroître l’accès aux médicaments. La somme des médicaments essentiels offerts par Pharmascience inc. atteint à ce jour plus de 70 millions de dollars.
For more than 20 years
Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine. Pharmascience’s total donations of essential medicine is close to $70 million.
b2b